Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)

Daniel T. Milton, Mark G. Kris, Jorge E. Gomez, Marc B. Feinstein

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Bronchorrhea is a condition in which voluminous sputum is produced daily, typically seen with bronchioloalveolar cell carcinoma (BAC). Unless the underlying cancer can be controlled, bronchorrhea causes substantial symptomatic distress. We report two cases of bronchorrhea associated with advanced BAC successfully treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib. Prompt resolution of these patients' bronchorrhea, dyspnea, and supplemental oxygen requirements are detailed. Given the limited success of alternative interventions, a trial of gefitinib should be considered for patients with bronchorrhea secondary to BAC.

Original languageEnglish
Pages (from-to)70-72
Number of pages3
JournalSupportive Care in Cancer
Volume13
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Keywords

  • BAC
  • Bronchorrhea
  • EGFR
  • Gefitinib

Fingerprint

Dive into the research topics of 'Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)'. Together they form a unique fingerprint.

Cite this